Who bought Mdco?

Who bought Mdco?

Novartis
Novartis announced today that it has entered into an agreement and plan of merger with The Medicines Company (NASDAQ: MDCO) to acquire the US-based biopharmaceutical company for USD 85.00 per share in cash, valuing the company at approximately USD 9.7 billion on a fully diluted equity basis.

What happened to the Medicines Company?

Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that it has completed the acquisition of The Medicines Company (the “Company”) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), with and into the Company, with the Company …

What drugs do Novartis make?

Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; production ceased 2020), terbinafine ( …

Who started the Medicines Company?

Clive Meanwell
Medicines Company (The)/Founders

The Medicines Company Origins It was founded by Dr. Clive Meanwell in 1996, when he envisioned a better approach to drug development, while serving as Director of R&D at Hoffmann-La Roche.

Who developed Inclisiran?

Inclisiran (Leqvio®), a first-in-class small interfering RNA (siRNA)-based therapeutic, is being developed by Novartis for the treatment of hypercholesterolaemia. Synthetic siRNAs engage the endogenous RNA interference (RNAi) pathway to prevent the expression of select genes [1].

Does Novartis pay well?

How much does Novartis Healthcare pay per year? The highest-paying job at Novartis Healthcare is a Senior Manager Finance with a salary of ₹58.5 Lakhs per year. The top 10% of employees earn more than ₹25.06 lakhs per year. The top 1% earn more than a whopping ₹45.6 lakhs per year.

How much does the CEO of Novartis make?

Vasant Narasimhan made CHF10,381,792 in total compensation as Chief Executive Officer at Novartis in 2020. CHF1,743,750 was received as Total Cash, CHF8,349,099 was received as Equity and CHF288,943 was received as Pension and other forms of compensation.

Where is Inclisiran manufactured?

In December, the FDA rejected the drug thanks to what Novartis previously called “unresolved facility inspection-related conditions.” Now, the company is shifting finished drug production of the PCSK9 med from an Italian plant run by contractor Corden Pharma to its in-house facility in Schaftenau, Austria.